NT-proBNP plasma levels in different types of cancers diagnosed
before three years of follow-up
In the subgroup of patients developing cancer in the first 3 years of
follow-up, NT-proBNP levels were 519.8±706.5 (N=15) in those with
carcinoma and 480.4±143.0 pg/ml (N=11) in patients developing
adenocarcinoma (p=0.877). Lung and hematologic cancers (n=6) did not
have NT-proBNP levels significantly different to other tumors (n=24)
(428.5 [152.3, 1212.0] vs 257.5 [88.0, 981.3] pg/ml; p=0.402).